newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Benzinga
RP2 monotherapy achieved an objective response rate (ORR) of 19.0% (4/21 evaluable patients) RP2 in combination with nivolumab achieved an ORR of 19,1%.
RP2 monotherapy achieved a 19.0% objective response rate in advanced solid tumor patients.
KEY POINTS
RP2 plus nivolumab showed a median duration of response of 22.1 months.
Tumor regression occurred in both injected and non-injected lesions, indicating systemic immune activation.
RP1 plus nivolumab led to a 3-year survival rate of 47.8% in anti-PD-1 failed melanoma.
REPL Stock Catalyst: RP2 Data Presentation At ASCO
It enrolled 85 heavily pretreated patients with advanced solid tumors.
On Sunday, the company said, RP2 monotherapy achieved an objective response rate (ORR) of 19.0% (4/21 evaluable patients).
RP2 in combination with nivolumab achieved an ORR of 19.1%, with a disease control rate of 48.9%.
Median duration of response (DOR) was not reached in the monotherapy group and was 22.1 months in the combination group.
Tumor regression was observed in both injected and non-injected lesions, including in all 3 monotherapy responders who had non-injected lesions, demonstrating a systemic immune response beyond the site of injection.
On Saturday, Replimune presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab for anti-PD-1 failed melanoma.
RP1 (vusolimogene oderparepvec) plus nivolumab achieved a median overall survival (mOS) of 32.9 months. At 3 years, 47.8% of all treated patients remained alive, rising to 83.5% among responders.
The ORR was 33.6%, with a median DOR of 24.8 months; 44.8% of responders maintained their response at 3 years.
How Replimune (REPL) Ranks On Momentum And Market Performance
Below is the Benzinga Edge scorecard for Replimune Group, highlighting its strengths and weaknesses compared to the broader market:
Momentum: Weak (Score: 27.02) — Stock is underperforming the broader market.
The Verdict: Replimune Group’s Benzinga Edge signal reveals a momentum-driven story, indicating challenges in maintaining upward price action despite recent gains. Investors should monitor upcoming presentations and earnings closely to gauge future performance.
REPL Stock Price Activity: Replimune shares were up 7.02% at $9.295 during premarket trading on Monday, according to Benzinga Pro data.
Image via Shutterstock